118 related articles for article (PubMed ID: 23767290)
1. In vitro effects of new generation oxazaphosphorines on human promyelocytic leukemia cells.
Mazur L; Opydo-Chanek M; Stojak M; Niemeyer U
Folia Biol (Krakow); 2013; 61(1-2):31-40. PubMed ID: 23767290
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of new generation oxazaphosphorines on the size and viability of human acute myeloblastic leukemia cells.
Mazur L; Opydo-Chanek M; Wojcieszek K; Stojak M; Niemeyer U
Folia Biol (Krakow); 2012; 60(1-2):35-40. PubMed ID: 22428304
[TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
Opydo-Chanek M; Mazur L; Stojak M
Indian J Exp Biol; 2013 Aug; 51(8):615-22. PubMed ID: 24228385
[TBL] [Abstract][Full Text] [Related]
4. Induction of DNA breakage in U937 cells by oxazaphosphorines.
Mazur L; Opydo-Chanek M; Stojak M; Baran J; Niemeyer U
Folia Biol (Krakow); 2010; 58(1-2):15-20. PubMed ID: 20420190
[TBL] [Abstract][Full Text] [Related]
5. Design of new oxazaphosphorine anticancer drugs.
Liang J; Huang M; Duan W; Yu XQ; Zhou S
Curr Pharm Des; 2007; 13(9):963-78. PubMed ID: 17430192
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of oxazaphosphorines in childhood acute leukemia: preliminary report.
Styczyński J; Wysocki M; Debski R; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Acta Biochim Pol; 2002; 49(1):221-5. PubMed ID: 12136944
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of glufosfamide in childhood acute leukemia.
Styczynski J; Wysocki M; Kurylak A; Juraszewska E; Malinowska I; Stanczak E; Płoszynska A; Stefaniak J; Mazur B; Szczepanski T; Ras M
Anticancer Res; 2002; 22(1A):247-50. PubMed ID: 12017297
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and transport of oxazaphosphorines and the clinical implications.
Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
[TBL] [Abstract][Full Text] [Related]
9. Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects.
Delahousse J; Skarbek C; Desbois M; Perfettini JL; Chaput N; Paci A
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32784216
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide.
Struck RF; Schmid SM; Waud WR
Cancer Chemother Pharmacol; 1994; 34(3):191-6. PubMed ID: 8004750
[TBL] [Abstract][Full Text] [Related]
11. Glufosfamide as a new oxazaphosphorine anticancer agent.
Mazur L; Opydo-Chanek M; Stojak M
Anticancer Drugs; 2011 Jul; 22(6):488-93. PubMed ID: 21427562
[TBL] [Abstract][Full Text] [Related]
12. Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).
Kohn FR; Sladek NE
Biochem Pharmacol; 1987 Sep; 36(17):2805-11. PubMed ID: 2820422
[TBL] [Abstract][Full Text] [Related]
13. Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines.
Kohn FR; Landkamer GJ; Manthey CL; Ramsay NK; Sladek NE
Cancer Res; 1987 Jun; 47(12):3180-5. PubMed ID: 3034402
[TBL] [Abstract][Full Text] [Related]
14. Insights into oxazaphosphorine resistance and possible approaches to its circumvention.
Zhang J; Tian Q; Chan SY; Duan W; Zhou S
Drug Resist Updat; 2005 Oct; 8(5):271-97. PubMed ID: 16154799
[TBL] [Abstract][Full Text] [Related]
15. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines.
Kohn FR; Sladek NE
Biochem Pharmacol; 1985 Oct; 34(19):3465-71. PubMed ID: 2996550
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase.
Rekha GK; Sreerama L; Sladek NE
Biochem Pharmacol; 1994 Nov; 48(10):1943-52. PubMed ID: 7986206
[TBL] [Abstract][Full Text] [Related]
17. Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia.
Zaharko DS; Covey JM; Hörpel G
Invest New Drugs; 1984; 2(2):149-54. PubMed ID: 6469508
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent.
Dollner R; Dietz A; Kopun M; Helbig M; Wallner F; Granzow C
Anticancer Res; 2004; 24(5A):2947-51. PubMed ID: 15517901
[TBL] [Abstract][Full Text] [Related]
19. In vitro response of human pathological hematopoietic cells to cladribine.
Mazur L; Opydo-Chanek M; Stojak M; Janota B; Blicharski K; Wojcieszek K; Kłaput U; Borowicz P
Folia Biol (Krakow); 2013; 61(3-4):143-8. PubMed ID: 24279161
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine.
Maki PA; Sladek NE
Cancer Res; 1991 Aug; 51(16):4170-5. PubMed ID: 1868438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]